Cancer-Cell Specific Organometallic Ru(II) Complexes as Photosensitizers in Photodynamic Therapy

Informacje na temat projektu

OrganometRuPDT

Identyfikator umowy o grant: 839499

DOI

10.3030/839499

Projekt został zamknięty

Data podpisania przez KE 23 Kwietnia 2019

Data rozpoczęcia 1 Marca 2020

Data zakończenia 15 Lipca 2021

Finansowanie w ramach

• EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions

Koszt całkowity

€ 107 746,24

Wkład UE

€ 107 746,24

Koordynowany przez

ECOLE NATIONALE SUPERIEURE DE CHIMIE DE PARIS
France

Periodic Reporting for period 1 - OrganometRuPDT (Cancer-Cell Specific Organometallic Ru(II) Complexes as Photosensitizers in Photodynamic Therapy)

Okres sprawozdawczy: 2020-03-01 do 2021-04-30

Podsumowanie kontekstu i ogólnych celów projektu

Cancer is still one of the most common and deadly diseases in the world. The current therapies usually have lots of side effects and some tumours are resistant to the most common therapeutics. Therefore, there is a need to tackle these problems and find out new strategies. Photodynamic therapy (PDT) is a promising therapy based in the combined effect of light, oxygen and a photosensitizer (PS). The non-toxic photosensitizer is excited and activated by light and this energy is transfered to oxygen, promoting singlet oxygen, extremely reactive species able to kill cells.
This therapeutic mechanism allows better specificity, since only the tumoral cells will be irradiated after the injection of the PS and therefore, it will reduce side effects in patients. Moreover, it will address the acquired resistance in some tumours, improving significantly the diagnosis of some patients.
The overall objective is the development of some metal complexes to be used as photosensitizers for PDT, including synthesis and characterization, and the test of these complexes in vitro first, and then in vivo.

Prace wykonane od początku projektu do końca okresu sprawozdawczego oraz najważniejsze dotychczasowe rezultaty

The project has succeeded in the main objective: the design and synthesis of a metal complex, which absorbs in the red region of the spectrum. This is one of the most important features for the use of the metal complexes as photosensitizers for PDT. Then, the complexes were functionalised to an antibody (Ab) for selective deliver to cancer cells.
The exploitation will depend on the final results but the first approaches are promising. These results, in any case and always after publication or patent, will be disseminate in social networks, social media and in some conferences. Additionally, I will write a publication in my personal website: www.onepotscience.com.

Innowacyjność oraz oczekiwany potencjalny wpływ (w tym dotychczasowe znaczenie społeczno-gospodarcze i szersze implikacje społeczne projektu)

When finished, the project will have a huge impact in the improvement of cancer therapies. This will lead to a clear impact on society and how people with cancer can fight this disease. It will help not only general society, but also chemists, biochemists and doctors.
So far, we have succeed to connect a metal complex to a monoclonal antibody (mAb), what is one of the scarce examples of this kind of attachment/combination.
We are extremely excited about the final results, and hope to help a little bit in cancer research, and support cancer patients.

TOC graphics for the summary